Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31393937 | 1.00 | PTGDR2 (0.40) | PTGDR2SLC6A2SLC6A4ALDH1A1LMNA | |
| SCHEMBL16959297 | 0.86 | GABRA1 (0.42) | PTGDR2SLC6A2SLC6A4ALDH1A1LMNA | |
| SCHEMBL31393933 | 0.85 | PTGDR2 (0.37) | PTGDR2SLC6A2SLC6A4ACE2HPGD | |
| SCHEMBL27711594 | 0.83 | CYP2A6 (0.39) | LMNAKMT2A | |
| SCHEMBL27711595 | 0.83 | CYP2A6 (0.39) | LMNAKMT2A | |
| Hydrochloric Acid SCHEMBL32667795 | 0.81 | PTGDR2 (0.38) | PTGDR2SLC6A2SLC6A4ALDH1A1LMNA | |
| SCHEMBL24823061 | 0.78 | TRPA1 (0.44) | SLC6A2LMNAACE2HTT | |
| SCHEMBL6542407 | 0.77 | GABRA1 (0.43) | MAPTHPGDPDE2A | |
| SCHEMBL9463459 | 0.77 | F2RL1 (0.38) | SLC6A2SLC6A4ACE2MEN1KMT2A | |
| SCHEMBL9463804 | 0.77 | LMNA (0.41) | SLC6A4LMNAMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1227096-B1 | 4-OXOQUINOLIZINE ANTIMICROBIALS HAVING 2-PYRIDONE SKELETONS AS THE PARTIAL STRUCTURE | SATO PHARMA (JP) | 2004-09-22 | — | — | EP | disclosed |
| US-6525066-B2 | Bactericides; side effect reduction | SATO PHARMACEUTICAL CO., LTD. (JP) | 2003-02-25 | — | — | US | disclosed |
| US-20020173517-A1 | 4-Oxoquinolizine antimicrobial having 2-pyridone skeleton as partial structure | SATO PHARMACEUTICAL CO., LTD. (JP) | 2002-11-21 | — | — | US | disclosed |
| EP-1227096-A1 | 4-OXOQUINOLIZINE ANTIMICROBIALS HAVING 2-PYRIDONE SKELETONS AS THE PARTIAL STRUCTURE | Sato Pharmaceutical Co. Ltd. (JP) | 2002-07-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173517-A1 | 4-Oxoquinolizine antimicrobial having 2-pyridone skeleton as partial structure | IL4I1, TLR5, IFNG | PTGDR2 1726/4885SLC6A2 3943/4885SLC6A4 3377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.